However, in clinical trials, the combination of gemcitabine with IGF-1R inhibitor received little overall survival benefits in advanced pancreatic cancer patients (Philip et al., 2014; Fuchs et al., 2015). This evidence concerns the gene IGF1R and pancreatic neoplasm.